Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Jorge Cortes, MDVideo Insights | September 10, 2023
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
View More
Cecilia BrownChronic Myeloid Leukemia | August 3, 2023
Researchers reviewed data from 107 patients with CML who developed a T315I mutation in BCR-ABL1.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Blood Cancers Today Staff WritersChronic Myeloid Leukemia | June 3, 2023
In this poor-risk population of patients, 73% responded to the triplet.
Cecilia BrownChronic Myeloid Leukemia | April 24, 2023
A study suggests a rationale for targeting PRMT5 in patients with relapsed or refractory MCL who have high mutation burdens.
Cecilia BrownChronic Myeloid Leukemia | April 13, 2023
The story of The Max Foundation begins with its namesake, Maximiliano “Max” M. Rivarola.
Simona Soverini, PhDVideo Insights | December 28, 2022
Simona Soverini, PhD, discusses new molecular data on CML, remaining challenges, and potentially practice-changing data.
Leah SherwoodMeeting News | December 10, 2022
Countries with a lower sociodemographic index are underrepresented in clinical trials of TKIs for the treatment of CML.
Leah LawrenceChronic Myeloid Leukemia | December 10, 2022
The TKI ponatinib may be the optimal third-line therapy for patients with chronic myeloid leukemia.
Leah LawrenceChronic Myeloid Leukemia | December 9, 2022
Adherence to oral anticancer agents appeared to be good among adults with chronic myeloid leukemia (CML).
Leah SherwoodChronic Myeloid Leukemia | November 23, 2022
Jorge Cortes, MD, discusses the financial toxicity of FDA-approved drugs for malignant hematology and OPTIC trial results.
Cecilia BrownChronic Myeloid Leukemia | October 13, 2022
With a growing number of treatment options, clinicians need guidance on the best third-line options for patients with CML.
Cecilia BrownChronic Myeloid Leukemia | October 13, 2022
The FDA cleared an Investigational New Drug (IND) application for IkT-001Pro for the treatment of chronic myelogenous ...
Kerri FitzgeraldChronic Myeloid Leukemia | September 29, 2022
Blood Cancers Today Associate Editor Jerald Radich, MD, discusses the role of ddPCR for CML in the age of targeted therapies.
Kerri FitzgeraldChronic Myeloid Leukemia | September 29, 2022
SOHO President Moshe Talpaz, MD, shares how it feels to be back onsite for the Annual Meeting.
Cecilia BrownChronic Myeloid Leukemia | September 29, 2022
Of the dozens of posters that were displayed on the first evening of the SOHO Annual Meeting, eight were honored with awards.
Leah SherwoodChronic Myeloid Leukemia | September 27, 2022
International Chronic Myeloid Leukemia (CML) Day takes place on September 22.
Cecilia BrownMyelodysplastic Syndromes | September 13, 2022
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
Cecilia BrownPrint | August 8, 2022
The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies.
Leah LawrenceChronic Myeloid Leukemia | May 26, 2022
The phase I/II study will assess the safety and tolerability of the drug.
Editorial Board